SP16
Peptideexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 16, 2018 (NCT03651089)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05135624 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2021 | Serpin Pharma, LLC, University of Virginia |
| NCT04225533 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2020 | Serpin Pharma, LLC, Virginia Commonwealth University |
| NCT03651089 | Phase 1 | Jul 16, 2018 | George Mason University, Serpin Pharma, LLC, Virginia Commonwealth University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Serpin Pharma, LLC | For profit | 3 | 2 | 2 | 2018 |
| Virginia Commonwealth University | Academic/Hospital | 2 | 1 | 2 | 2018 |
| George Mason University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Virginia | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1